Potentially new isobaric metabolite of fluvastatin observed by LC-MS/MS during incurred sample analysis

Bioanalysis

Volumn 3, Issue 16, 2011, Pages 1827-1835

  Taillon, Marie Pierre ^a   Cté, Cynthia ^a   Furtado, Milton ^a   Garofolo, Fabio ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUINDOSTATIN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG ISOLATION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; ISOMER; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; RELIABILITY; SEPARATION TECHNIQUE; SINGLE DRUG DOSE;

ANTICHOLESTEREMIC AGENTS; CHROMATOGRAPHY, LIQUID; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; MALE; MASS SPECTROMETRY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM;

EID: 80052476021     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.186     Document Type: Article

References (24)

1. Toreson H, Eriksson BM. Determination of fluvastatin enantiomers and the racemate in human blood plasma by liquid chromatography and fluorometric detection. J. Chromatogr. A 729, 13-18 (1996). (Pubitemid 26135002)
2. Al-Rawithi S, Hussein RF, Alzahrani A. Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection. Ther. Drug Monit. 25, 1, 88-92 (2003). (Pubitemid 36139831)
3. Lanchote VL, Rocha A, Vieira de Albuquerque FU, Coelho EB, Bonato PS. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. J. Chromatogr. B 765, 81-88 (2001). (Pubitemid 33055811)
4. Di Pietro G, Coelho EB, Geleilete TM, Marques MP, Lanchote VL. Chiral evaluation of fluvastatin in human plasma by high-performance liquid chromatography electrospray mass spectrometry. J. Chromatogr. B 832, 256-261 (2006). (Pubitemid 43339955)
5. Nirogi RVS, Kandikere VN, Shrivastava W, Mudigonda K, Datla PV. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of fluvastatin in human plasma: validation and its application to pharmacokinetic studies. Rapid Commun. Mass Spectrom. 20, 1225-1230 (2006).
6. Gonzalez O, Iriarte G, Rico E et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(28), 2685-2692 (2010).
7. Jemal M, Xia YQ. The need for adequate chromatographic separation in the quantitative determination of drugs in biological samples by high performance liquid chromatography with tandem mass spectrometry. Rapid Commun. Mass. Spectrom. 19, 97-106 (1999). (Pubitemid 29064513)
8. Yan Z, Caldwell GW, Jones WJ, Masucci JA. Cone voltage induced in-source dissociation of glucuronides in electrospray and implications in biological analyses. Rapid Commun. Mass. Spectrom. 17, 1433-1442 (2003). (Pubitemid 36791149)
9. Ramanathan R, Su AD, Alavarez N et al. Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylkated compounds. Anal. Chem. 72, 1352-1359 (2000). (Pubitemid 30163798)
10. Peiris DM, Lam W, Micheal S, Ramanathan R. Distinguishing N-oxide and hydroxyl compounds: impact of heated capillary/heated ion transfer ion transfer tube in inducing atmospheric pressure ionization source decompositions. J. Mass Spectrom. 39, 600-606 (2004). (Pubitemid 38878316)
11. An G, Ruszaj DM, Morris ME. Interference of a sulfate conjugate in quantitative liquid chromatography/tandem mass spectrometry through in-source dissociation. Rapid Commun. Mass. Spectrom. 24, 1817-1819 (2010).
12. Dicaire C, Bérubé ER, Furtado M, Garofolo F. Impact of oxcarbazepine sulfate metabolite on incurred sample reproducibility and quantification of oxcarbazepine. Bioanalysis 3(9), 973-982 (2011).
13. Jemal M, Ouyang Z. The need for chromatographic and mass resolution in liquid chromatography/tandem mass spectrometric methods used for quantification of lactones and corresponding hydroxy acids in biological samples. Rapid Commun. Mass Spectrom. 14, 1757-1765 (2000).
14. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin. Chem. 46, 365-372 (2000). (Pubitemid 30152262)
15. Ferreirós N, Dresen S, Alonso RM, Weinmann W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855(2), 134-138 (2007). (Pubitemid 47212003)
16. Côté C, Lahaie M, Latour S et al. Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation: ramiprilat case study. Bioanalysis 3(9), 951-965 (2011).
17. Jemal M, Ouyang Z, Xia Y-Q. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 24, 2-19 (2010).
18. Dain JG, Fu E, Gorski J, Nicoletti J, Scallen TJ. Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. 21, 567-572 (1993). (Pubitemid 23221749)
19. Grobelny P, Viola G, Vedaldi D, Dall'Acqua F, Gliszczyńska-Swiglo A, Mielcarek J. Photostability of pitavastatin - a novel HMG-CoA reductase inhibitor. J. Pharm. Biomed. Anal. 50, 597-601 (2009).
20. Mielcarek J, Kula M, Zych R, Grobelny P. Kinetic studies on fluvastatin photodegradation in solution. React. Kinet. Catal. Lett. 86, 119-126 (2005). (Pubitemid 41240170)
21. Cermola F, DellaGreca M, Iesce MR et al. Irradiation of fluvastatin in water structure elucidation products. J. Photochem. Photobiol. A Chem. 189, 264-271 (2007).
22. Tanaka K, Yasuhara M, Suzumura K, Narita H. Suzuki T. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn. J. Pharmacol. 86, 289-296 (2001).
23. Aoki S, Ikeda K, Yamamura M, Kojo S. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma. Biol. Pharm. Bull. 24, 123-126 (2001). (Pubitemid 32177770)
24. Nakamura T, Nishi H, Kokusenya Y, Hirota K, Miura Y. Mechanism of antioxidative activity of fluvastatin - determination of the active position. Chem. Pharm. Bull. 48, 235-237 (2000). (Pubitemid 30136946)